...
首页> 外文期刊>Pediatric nephrology: journal of the International Pediatric Nephrology Association >Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group.
【24h】

Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group.

机译:干细胞移植后持续进行肾脏替代治疗(CRRT)。预期的儿科CRRT注册机构小组的报告。

获取原文
获取原文并翻译 | 示例

摘要

Pediatric stem cell transplant (SCT) recipients commonly develop acute renal failure (ARF). We report the demographic and survival data of pediatric SCT patients enrolled in the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry. Since 1 January 2001, 51/370 (13.8%) patients entered in the ppCRRT Registry had received a SCT. Median age was 13.63 (0.53-23.52) years. The primary reasons for the initiation of continuous renal replacement therapy (CRRT) were treatment of fluid overload (FO) and electrolyte imbalance (49%), FO only (39%), electrolyte imbalance only (8%) and other reasons (4%). The CRRT modalities included continuous veno-veno hemodialysis (CVVHD), 43%, continuous veno-veno hemofiltration (CVVH), 37% and continuous veno-veno hemodiafiltration (CVVHDF), 20%. Seventy-six percent had multi-organ dysfunction syndrome (MODS), 72% received ventilatory support and the mean FO was 12.41 +/- 3.70%. Forty-five percent of patients survived. Patients receiving convective therapies had better survival rates (59% vs 27%, P < 0.05). Patients requiring ventilatory support had worse survival (35% vs 71%, P < 0.05). Mean airway pressure (Paw) at the end of CRRT was lower in survivors (8.7 +/- 2.94 vs 25.76 +/- 2.03 mmH(2)O, P < 0.05). Development of high mean airway pressure in non-survivors is likely related to non-fluid injury, as it was not prevented by early and aggressive fluid management by CRRT therapy.
机译:小儿干细胞移植(SCT)受者通常会发展为急性肾衰竭(ARF)。我们报告了在前瞻性小儿连续性肾脏替代治疗(ppCRRT)注册中登记的小儿SCT患者的人口统计学和生存数据。自2001年1月1日以来,进入ppCRRT注册中心的51/370(13.8%)患者接受了SCT。中位年龄为13.63(0.53-23.52)岁。开始进行持续性肾脏替代治疗(CRRT)的主要原因是治疗液体超负荷(FO)和电解质失衡(49%),仅FO(39%),仅电解质失衡(8%)和其他原因(4% )。 CRRT模式包括连续性静脉-静脉血液透析(CVVHD),43%,连续性静脉-静脉血液滤过(CVVH),37%和连续性静脉-静脉血液透析滤过(CVVHDF),20%。 76%的人患有多器官功能障碍综合征(MODS),72%的患者接受了通气支持,平均FO为12.41 +/- 3.70%。百分之四十五的患者存活。接受对流疗法的患者生存率更高(59%比27%,P <0.05)。需要通气支持的患者生存较差(35%vs 71%,P <0.05)。幸存者中CRRT结束时的平均气道压力(Paw)较低(8.7 +/- 2.94对25.76 +/- 2.03 mmH(2)O,P <0.05)。非幸存者中平均气道高压力的形成可能与非流体损伤有关,因为CRRT疗法无法通过早期积极的液体管理来预防。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号